



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 08/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	GROUP: Not Known

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
<del>10/14</del>	AA	5,077,292	12/31/1991	Gluchowski			
	AB	5,034,406	7/23/1991	Gluchowski			
	AC	5,021,416	6/4/1991	Gluchowski			
	AD	5,130,441	7/14/1992	Gluchowski			
	AE	5,066,664	11/19/1991	Gluchowski			
	AF	5,151,440	9/29/1992	Gluchowski			
	AG	5,112,822	5/12/1992	Gluchowski			
	AH	5,091,528	2/25/1992	Gluchowski			
	AI	5,231,096	7/27/1993	Gluchowski			
	AJ	5,198,442	3/30/1993	Gluchowski			
	AK	5,580,892	12/3/1996	Garst et al			
	AL	5,552,403	9/3/1996	Burke et al			
	AM	5,663,189	9/2/1997	Maurer et al			
	AN	5,215,991	6/1/1993	Burke et al			
	AO	5,180,721	1/19/1993	Burke et al			
	AP	5,561,132	10/1/1996	Burke et al			
	AQ	5,621,113	4/15/1997	Boyd et al			
	AR	RE 32,400	4/1987	Karjalainen et al	574	392	
	AS	4,443,466	4/1984	Karjalainen et al	424	277	
	AT	4,496,572	1/1985	Cross et al	519	337	
	AU	4,540,705	9/1985	Bailey	574	401	
	AV	5,151,526	9/1992	Hsu et al	548	3151 X	
	AW	5,750,720	5/1998	Boyd et al II	548	3151	

EXAMINER Flora D. Royal

DATE CONSIDERED 09-18-2001

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 09/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	GROUP: Not Known

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
<i>7/21/01</i>	AX	0 194 984	9/17/1986	EPO	<i>+</i>	<i>+</i>	
<i>↑</i>	AY	0 304 910	3/1/1989	EPO	<i>+</i>	<i>+</i>	
	BB	WO 97/35858	10/2/1997	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
	BC	WO 97/31636	9/4/1997	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
	BD	WO 95/19968	7/27/1995	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
	BE	WO 97/03079	1/30/1997	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
	BF	WO 97/15302	5/1/1997	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
	BG	WO 95/16449	6/22/1995	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
	BH	WO 97/12874	4/10/1997	<del>WIPO</del> PCT <i>ORION</i>	<i>+</i>	<i>+</i>	
	BI	WO 94/07866	4/14/1994	<del>WIPO</del> PCT <i>TOKYO</i>	<i>+</i>	<i>+</i>	
	BJ	WO 96/01813	1/15/1996	<del>WIPO</del> PCT	<i>+</i>	<i>+</i>	
<i>↓</i>	BK	1/242571	9/1989	JAPAN <i>KIYAHARA ET AL</i>	<i>+</i>	<i>+</i>	
<i>7/21/01</i>	BL	4/267130	1992	JAPAN	<i>+</i>	<i>+</i>	

EXAMINER *Hayden H. Hye* DATE CONSIDERED *09-18-2001*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
FORM PTO-1449

Sheet 3 of 3

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

<b>ATTY. DOCKET:</b> 17243CIP3(AP)	<b>SERIAL NO.:</b> 09/815,362
<b>APPLICANT:</b> Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
<b>FILING DATE:</b> March 21, 2001	<b>GROUP:</b> Not Known

### OTHER PRIOR ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	BM	Bylund et al, 1994, Pharmacol Rev. <u>46</u> , pp. 121-136, "International Union of Pharmacology Nomenclature of Adrenoceptors"
	BN	Shimizu et al, 1969, J. Neurochem. <u>16</u> , pages 1609-1619, "A Radiosotopic Method For Measuring The Formation of Adenosine 3', 5' -Cyclic Monophosphate in Incubated Slices Of Brain"
	BO	Messier et al, 1995, Pharmacol. Toxicol. <u>76</u> , pages 308-311, "High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells"
	BP	Neve et al, 1992, J. Biol. Chem. <u>267</u> , pages 25748-25753, "Dopamine D2 Receptor Stimulation of Na <sup>+</sup> /H <sup>+</sup> Exchange Assessed by Quantification of Extracellular Acidification"
	BQ	Williams et al, 1990, J. Auton. Pharmacol, 10, 247, pages 109-118, " $\alpha$ 2- adrenoceptor antisecretory responses in the rat jejunum"
	BR	Fondacaro et al, 1988, Vol. 247, No. 2, pages 481-486, "The Journal of Pharmacology and Experimental Therapeutics"
	BS	White et al, 1975, Communications/Synthesis, pages 602-3, "A Convenient Procedure for the Preparation of 2-endo-Hydroxy-cis-bicyclo [3.3.0]octane"
	BT	Conklin et al, Nature, 1993, Vol. 363, pages 274-6, "Substitution of three amino acids switches receptor specificity of G <sub>q</sub> $\alpha$ to that of G <sub>i</sub> $\alpha$ "
	BU	Schaaf et al, J. Med. Chem. 1983, Vol. 26, pages 328-334, "Structure-Activity Studies of Configurationally Rigid Arylprostaglandins"
	BV	Kihara et al, "Preparation of imidazole derivatives as drugs", 6001 Chemical Abstracts, Columbus, Ohio, U.S. Vol. 112 (4/9/1996), No. 16, XP-002098179
	BW	Zhang et al, "Medetomidine Analogs as $\alpha$ 2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with $\alpha$ 2-Adrenoceptors Involving a 'Methyl Pocket' ", J. Med. Chemc. 1997, 40. pgs. 3014-3024

EXAMINER Wayne D. Hugel

DATE CONSIDERED 09-18-2001

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.